Erbitux trial flawed from the beginning, committee finds.
Randal
Judith
J
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000068818:Cetuximab; D002986:Clinical Trials as Topic / Q000592:standards*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D017277:Drug Approval; D004357:Drug Synergism; D006801:Humans; D000077146:Irinotecan; D012107:Research Design / Q000592:standards; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077146:Irinotecan; D000068818:Cetuximab; D002166:Camptothecin